NeoGenomics (NASDAQ:NEO) Downgraded by Zacks Investment Research to Sell

NeoGenomics} stock has undergone multiple analysts rating changes in the recent past.  NeoGenomics Downgraded by Zacks Investment Research on 10/27/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More NeoGenomics (NASDAQ:NEO) Downgraded by Zacks Investment Research to Sell

Reports Strong First-Quarter Financial Results NASDAQ:IRTC, NASDAQ:OPRT, NASDAQ:CABA, NASDAQ:NEO

Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis…

View More Reports Strong First-Quarter Financial Results NASDAQ:IRTC, NASDAQ:OPRT, NASDAQ:CABA, NASDAQ:NEO

Factors Likely to Have Influenced Earnings Results NeoGenomics (NASDAQ:NEO)

Earnings results for NeoGenomics , Analyst Opinion on NeoGenomics , Earnings and Valuation of (NASDAQ:NEO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Factors Likely to Have Influenced Earnings Results NeoGenomics (NASDAQ:NEO)

Does Earnings Surprise History Hold Any Clue for NeoGenomics (NASDAQ:NEO)

Earnings results for NeoGenomics , Analyst Opinion on NeoGenomics , Earnings and Valuation of (NASDAQ:NEO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Does Earnings Surprise History Hold Any Clue for NeoGenomics (NASDAQ:NEO)

Analyst Valuation and EPS Growth for NeoGenomics (NASDAQ:NEO)

Earnings results for NeoGenomics , Analyst Opinion on NeoGenomics , Earnings and Valuation of (NASDAQ:NEO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Analyst Valuation and EPS Growth for NeoGenomics (NASDAQ:NEO)

Did they just beat EPS? NeoGenomics (NASDAQ:NEO)

Earnings results for NeoGenomics , Analyst Opinion on NeoGenomics , Earnings and Valuation of (NASDAQ:NEO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Did they just beat EPS? NeoGenomics (NASDAQ:NEO)